Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000167892 | SCV000218538 | pathogenic | Lynch syndrome | 2017-01-19 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 8-9 of the EPCAM gene. The 5' boundary is likely confined to intron 7. The 3' end of this event is unknown, as it extends through the termination codon beyond the assayed region for this gene, but is likely confined to the intergenic region between the EPCAM and MSH2 genes, as no copy number variations were detected in MSH2. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated EPCAM protein. Similar deletions of exons 8-9 have been reported in individuals and families affected with Lynch syndrome (PMID: 23454724, 21309036, 21227399, 20864635, 22243433). Deletions involving the 3' region of the EPCAM gene (minimally, exon 9) are known to cause Lynch syndrome. These deletions lead to transcriptional read-through from the EPCAM promoter into the adjacent MSH2 gene, resulting in hypermethylation of the MSH2 promoter and silencing of MSH2 expression (PMID: 19098912, 19177550, 21309036). For these reasons, this variant has been classified as Pathogenic. |